Greenwich LifeSciences, Inc. GLSI 深 沪
等待开盘 07-22 09:30:00 美东时间
14.65
+0.580
+4.12%
华盛通- 最 高15.36
- 今 开13.85
- 成交量 32.50万股
- 最 低 13.04
- 昨 收 14.07
- 总市值 2.15亿
- 52周最高 34.10
- 市盈率 静 --
- 换手率 2.21%
- 52周最低 7.78
- 委 比 90.48%
- 总股本 1467.82万
- 历史最高 158.07
- 量 比 1.20
- 振 幅 16.49%
- 历史最低 3.262
- 每 手 1
- 风险率 7.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
今天 11:35
Greenwich LifeSciences wins EMA clearance to combine HLA patient groups in FLAMINGO-01 trial
Greenwich LifeSciences wins EMA clearance to combine HLA patient groups in FLAMINGO-01 trial Greenwich LifeSciences secured European Medicines Agency clearance to enroll HLA-A02 and non-HLA-A02 patients in the same randomized arms of FLAMINGO-01. Protocol alignment enables all 170-180 US and Europea
07-16 19:33
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of ...
07-16 19:31
Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial
All European and US Sites to Treat Patients with Commercially Manufactured GP2 The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP...
07-09 18:04
EMA clears Greenwich Lifesciences’ commercially manufactured GP2 for use in FLAMINGO-01 trial in Europe
EMA clears Greenwich Lifesciences’ commercially manufactured GP2 for use in FLAMINGO-01 trial in Europe EMA review cleared use of Greenwich LifeSciences’ commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer recurrence trial in Europe. Move aligns European sites with the US, w
07-09 18:01
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences announced updates on its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. All US and European sites are now using commercially manufactured GP2, with European approval following US clearance. The trial has expanded to approximately 170-180 sites globally. Over 1,300 patients have been screened, with the non-HLA-A*02 arm fully enrolled. Preliminary data shows ...
07-09 10:00
Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.31) by 87.1 percent. This is a 4.92 percent increase over losses of $(0.61) per share
06-02 05:50
Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
06-01 18:11
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
Greenwich LifeSciences provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025, which is nearing final approval. The filing delay was due to accounts payable adjustments related to its large Phase III clinical trial and increased patient enrollment in Europe. The company believes these adjustments are not material and have improved its financial estimations. The Phase III FLAMINGO-01 trial has enrolled over 1,300 p...
06-01 10:00
Greenwich LifeSciences Receives Nasdaq Noncompliance Notice
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated
05-23 04:31
